Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (VTGN)

Core Viewpoint - A securities class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that acquired Vistagen securities between April 1, 2024, and December 16, 2025 [1]. - The Complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the PALISADE-3 trial [2]. Group 2: Trial Results - The PALISADE-3 Phase 3 study did not show a statistically significant improvement on the primary endpoint, which was the change on the Subjective Units of Distress Scale (SUDS) [2]. - The trial results indicated no treatment difference between fasedienol and placebo for the secondary endpoints [2]. Group 3: Market Reaction - Following the announcement of the trial results, Vistagen's stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of over 80% [3].